Grupo Espanol De Tumores Neuroendocrinos

This study compares two schedules of the drug Lu177-Dotatate for people with slow-growing, advanced midgut neuroendocrine tumors. One group gets treatment every 8 weeks, the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-related side eff…

This phase 3 trial tests whether a targeted radiation therapy (177Lu-edotreotide) works better than a standard drug (everolimus) for people with certain lung or thymus neuroendocrine tumors. About 170 adults with advanced tumors that have receptors for a specific hormone will be …

This study tests a new drug called tarlatamab, which helps the immune system attack cancer cells. It is for people with advanced neuroendocrine carcinomas of the digestive system or unknown origin. The study will see if tarlatamab works better alone or with standard chemotherapy …